Executive Summary / Key Takeaways
-
Strategic Pivot from Volatile Revenue: DocGo's 71% revenue decline in 2025 reflects a deliberate exit from low-margin, volatile migrant contracts that once comprised 73% of revenue. This creates a foundation for sustainable growth in higher-quality payer/provider relationships, with non-migrant Mobile Health revenue surging 47% in Q4 2025.
-
Liquidity Challenges Threaten Turnaround: Despite generating $34.5 million in operating cash flow in 2025, DocGo faces a going concern warning, Nasdaq delisting notice, and covenant non-compliance. The company must execute on cost cuts and receivables collection to strengthen its position over the next 12 months.
-
Transportation as Financial Anchor, Mobile Health as Growth Engine: The Transportation segment's steady 3.8% growth and 32.8% gross margins provide stable cash generation, while Mobile Health's pivot to care gap closure, RPM, and SteadyMD integration offers 40% projected growth in 2026. This segment mix shift is critical for margin expansion.
-
Technology Differentiation in Fragmented Markets: DocGo's proprietary dispatch platform and AI-driven workflows enable faster response times and integrated "phygital" care delivery that pure-play competitors like Modivcare (MODV) and Teladoc (TDOC) cannot replicate. The significance lies in whether the company can fund operations long enough to scale this advantage.
-
Execution Risk Defines Investment Asymmetry: Management's 2026 guidance implies a path toward profitability through $5-10 million in EBITDA losses and $20-24 million in cost savings by 2027. Success hinges on hiring 700-800 EMTs to capture outsourced demand, SteadyMD integration by Q2 2026, and collecting $20 million in delayed NYC receivables.
Setting the Scene: The Last-Mile Healthcare Specialist
DocGo Inc., founded in 2015 as Ambulnz and headquartered in New York, operates at the intersection of two massive healthcare trends: the $250 billion at-home healthcare market and the chronic disease crisis. The company built its business on delivering healthcare at any address through an integrated platform combining medical transportation, mobile health services, and virtual care management. This vertically integrated model stands apart in a fragmented landscape of point solutions.
The company's origins trace to a traditional ambulance operator, but its strategic evolution reveals a deliberate push up the healthcare value chain. The 2021 SPAC merger provided $158 million in growth capital, funding acquisitions that expanded capabilities from pure transport into mobile phlebotomy, remote patient monitoring, and virtual care. This transformation positioned DocGo to capture the shift from facility-based care to proactive, at-home interventions that payers use to manage escalating medical loss ratios .
However, 2025 was the year DocGo's strategy collided with market reality. The wind-down of migrant-related services, which peaked at 73% of 2023 revenue, created a revenue cliff. DocGo is sacrificing short-term scale for long-term sustainability, betting that its integrated platform can capture higher-margin, recurring revenue from payers and providers. The central question is whether the balance sheet can survive the transition.
Technology, Products, and Strategic Differentiation
DocGo's competitive moat rests on a proprietary technology platform that orchestrates the entire care delivery chain. Unlike Modivcare, which operates as a brokerage matching patients with third-party transporters, DocGo's system directly controls dispatch, clinical workflows, and patient engagement. This enables response times measured in minutes rather than hours, a critical differentiator for both emergency and non-emergency medical transport. The platform's AI integration, including the AgenTeq AI agent that automates appointment reminders in seven languages, saves approximately 10% of live operator time.
The October 2025 acquisition of SteadyMD for $25-30 million in projected 2026 revenue represents more than a virtual care add-on; it creates a 50-state clinical network that can provide virtual follow-up for mobile health visits. This integration, targeted for completion by Q2 2026, allows DocGo to offer a "phygital" continuum: a clinician travels to the patient's home for blood draws or primary care, then SteadyMD's network handles ongoing monitoring and chronic disease management. This closed loop increases patient retention and lifetime value while reducing costly ED visits—DocGo estimates it prevented 91,000 unnecessary emergency department visits in 2025, saving the healthcare system $285 million.
The technology's economic impact appears in segment margins. Transportation Services achieved 32.8% adjusted gross margins in Q4 2025, the highest since 2024, despite overtime rates running at 13% of hourly wages. The platform's routing optimization and real-time dispatch reduce deadhead miles and improve asset utilization, enabling DocGo to capture demand that would otherwise be outsourced. The company estimates it assigned over 26,000 trips to competitors in the past year due to capacity constraints.
However, technology alone cannot overcome structural cost disadvantages. DocGo's fleet of 582 U.S. vehicles and nearly 3,600 employees creates a high fixed-cost base that virtual-only competitors like Teladoc and LifeMD (LFMD) avoid. While LifeMD achieves 87% gross margins with its asset-light model, DocGo's blended gross margin hovers around 30-33%. The technology moat must therefore generate sufficient pricing power to offset this cost structure.
Financial Performance & Segment Dynamics: Evidence of Strategy
DocGo's 2025 financial results reflect a significant transition. Total revenue declined 47.7% to $322.2 million, driven by the migrant contract wind-down. Mobile Health Services fell 71.3% to $121.4 million. Yet, non-migrant Mobile Health revenue surged 47% in Q4 2025, driven by care gap closures, remote patient monitoring, and two months of SteadyMD contributions. This demonstrates that the underlying payer/provider business is growing, albeit from a smaller base.
The Transportation Services segment provides the financial anchor. Revenue grew 3.8% to $200.8 million on 4.4% volume growth, with trip volumes reaching 296,014. Adjusted gross margins expanded to 32.8% in Q4, up from 30.1% in 2024, despite aggressive hiring ahead of a major New York customer launch. This margin expansion reflects pricing discipline and operational leverage. The segment's stability funded the Mobile Health pivot, generating $34.5 million in operating cash flow despite a $196.4 million net loss.
The net loss includes $88 million in goodwill and intangible asset impairments, which represents a write-down of acquisition premiums rather than operating cash burn. Excluding these non-cash charges, the underlying EBITDA loss of $28.6 million stems primarily from SG&A deleverage as revenue fell faster than costs could be reduced. Management has since implemented a reduction in force and launched an efficiency initiative targeting $20-24 million in annual savings by 2027.
The balance sheet reveals both resources and constraints. At year-end 2025, DocGo held $51 million in unrestricted cash with $84.9 million in working capital. However, the company was not in compliance with its minimum liquidity covenant and received a Nasdaq delisting notice in January 2026 when the stock fell below $1.00. The $20 million in delayed NYC migrant receivables represents a critical component of the company's liquidity position.
Outlook, Management Guidance, and Execution Risk
Management's 2026 guidance targets 15-23% revenue growth over the 2025 base, with Transportation reaching $215 million and Mobile Health hitting $85-88 million. The adjusted EBITDA loss guidance of $5-10 million represents a significant improvement from 2025, contingent on $5-6 million in cost savings and gross margin expansion to a 33% blended rate.
These targets rely on specific operational improvements. The Transportation segment's margin expansion, combined with overtime rates expected to decline from 13% to sub-10% in 2026, suggests a path to higher EBITDA margins. Hiring 700-800 EMTs could capture $10-15 million in previously outsourced revenue. The July 2025 New York customer launch should begin contributing meaningfully in 2026.
The Mobile Health outlook hinges on SteadyMD integration and payer contract expansion. SteadyMD's Q4 performance—$6.1 million in revenue and 37% gross margins—demonstrates scalability. Management's target of $25 million in 2026 SteadyMD revenue assumes successful consolidation of provider networks by Q2 2026. The care gap closure program's expansion to 1.45 million assigned lives provides a foundation for $60 million in baseline payer/provider revenue beyond SteadyMD.
The critical execution variable is cash management. Management expects to exit 2026 with $65 million in cash, a trajectory that requires collecting the remaining $20 million in NYC receivables, achieving revenue targets, and delivering promised cost savings. Any slippage on these variables could necessitate additional capital measures.
Risks and Asymmetries: What Could Break the Thesis
The going concern warning in the 2025 10-K reflects a genuine liquidity challenge. If DocGo cannot resolve its covenant non-compliance or collect NYC receivables, access to credit lines could be restricted. This risk is compounded by the Nasdaq delisting notice; while the company has until July 2026 to regain compliance, the current stock price reflects significant market skepticism.
Customer concentration remains a threat despite the pivot. One customer still represents 33% of 2025 revenue. While government work is no longer the core strategy, the loss of any major payer contract could impact the 2026 revenue target. The payer/provider vertical's projected growth assumes existing contracts expand as planned.
Labor costs present a structural vulnerability. DocGo's 3,600 employees and fleet of 582 vehicles create fixed costs that virtual competitors avoid. While management targets overtime reduction, a tight labor market could force wage inflation. The company's high NPS score suggests strong employee satisfaction, but this must translate into lower recruitment and retention costs to aid margins.
The AI integration strategy also carries execution risk. DocGo uses third-party AI enhancements, but competitors like Teladoc and Amwell (AMWL) have significant R&D resources. If AI-driven efficiency gains fail to materialize, DocGo's cost structure disadvantage versus virtual-only players will persist.
Conversely, there is upside in the Transportation segment's embedded demand. The 26,000 outsourced trips represent $10-12 million in revenue that could be captured by hiring available staff. If DocGo accelerates hiring beyond the 700-800 target, each additional EMT generates approximately $150,000 in annual revenue at 30%+ gross margins.
Valuation Context: Distressed Pricing with Turnaround Optionality
At $0.57 per share, DocGo trades at an enterprise value of $34.45 million, or 0.11x TTM revenue of $322.2 million. This multiple reflects significant distress. The price-to-operating cash flow ratio of 1.63x suggests the market is pricing in a high probability of permanent capital impairment.
Peer comparisons highlight the valuation gap. Teladoc trades at 0.37x revenue with 69.5% gross margins. LifeMD commands 0.86x revenue with 85.7% gross margins and positive profitability. Amwell trades at 0.37x revenue despite declining revenue. DocGo's 0.11x multiple represents a substantial discount to these peers, pricing in a high risk of failure.
The balance sheet provides some cushion, with a 2.26 current ratio and $84.9 million in working capital. However, the $51 million cash position against projected 2026 losses leaves little room for error. Debt-to-equity of 0.23x is manageable, but covenant issues remain a primary concern.
For investors, the valuation is binary: if DocGo executes its 2026 plan and stabilizes its cash position, the stock could re-rate toward 0.5-1.0x revenue, implying significant upside. If the company fails to collect receivables or meet targets, further dilution or asset sales may be required.
Conclusion: A Turnaround on Life Support
DocGo's investment thesis revolves around whether management can execute a strategic pivot to a higher-margin model before liquidity is exhausted. The evidence from 2025 is mixed but shows progress. The exit from migrant contracts has revealed a core business growing at double-digit rates. The Transportation segment's margin expansion and the Mobile Health segment's 47% non-migrant growth in Q4 demonstrate the platform's value.
However, the going concern warning and delisting notice are immediate threats. Management's 2026 guidance provides a path to stabilization but requires flawless execution on hiring, cost reduction, and receivables collection. Any misstep could trigger a liquidity crisis.
The competitive landscape offers both validation and warning. DocGo's integrated model fills a gap that pure-play virtual and transportation competitors cannot address. Yet the company's financial distress leaves it vulnerable to better-capitalized rivals. For investors, DocGo represents a high-risk turnaround bet where the critical variables to monitor are cash collection from NYC, hiring progress in Transportation, and the SteadyMD integration timeline.
